Roy A Mariuzza Selected Research

Cadherins (E-Cadherin)

7/2009

Structure of natural killer cell receptor KLRG1 bound to E-cadherin reveals basis for MHC-independent missing self recognition.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Roy A Mariuzza Research Topics

Disease

21	Neoplasms (Cancer) 03/2024 - 01/2002
6	Septic Shock (Toxic Shock Syndrome) 01/2013 - 09/2006
5	Melanoma (Melanoma, Malignant) 11/2013 - 05/2002
2	Virus Diseases (Viral Diseases) 12/2023 - 10/2022
2	COVID-19 01/2023 - 10/2022
2	Infections 12/2016 - 10/2012
2	Autoimmune Diseases (Autoimmune Disease) 11/2012 - 11/2007
2	Multiple Sclerosis 03/2011 - 09/2005
2	Purpura Fulminans 01/2011 - 07/2007
1	Reinfection 01/2023
1	Type 2 Diabetes Mellitus (MODY) 12/2021
1	Tuberculosis (Tuberculoses) 01/2017
1	Chronic Hepatitis C 12/2016
1	Necrosis 07/2015
1	Inflammatory Bowel Diseases (Inflammatory Bowel Disease) 01/2013
1	Foodborne Diseases 07/2007
1	Human Influenza (Influenza) 09/2006

Drug/Important Bio-Agent (IBA)

10	Peptides (Polypeptides)IBA 01/2023 - 05/2002
7	LigandsIBA 01/2020 - 01/2002
6	T-Cell Antigen Receptors (T-Cell Receptor)IBA 01/2023 - 09/2005
6	SuperantigensIBA 01/2013 - 09/2006
5	EpitopesIBA 01/2023 - 04/2007
5	HLA-DR1 Antigen (HLA DR1 Antigen)IBA 09/2012 - 05/2002
5	Histocompatibility Antigens Class IIIBA 09/2012 - 09/2005
4	Proteins (Proteins, Gene)FDA Link 01/2023 - 11/2016
4	CytokinesIBA 01/2011 - 09/2006
3	Monoclonal AntibodiesIBA 03/2024 - 06/2015
3	Antiviral Agents (Antivirals)IBA 12/2023 - 10/2012
3	AntibodiesIBA 10/2023 - 08/2013
3	Triose-Phosphate Isomerase (Triosephosphate Isomerase)IBA 09/2012 - 05/2002
3	AntigensIBA 06/2010 - 05/2002
2	Lymphocyte Activation Gene 3 ProteinIBA 10/2023 - 10/2022
2	VaccinesIBA 01/2023 - 11/2013
2	HLA-A2 Antigen (HLA A2 Antigen)IBA 10/2022 - 01/2022
2	Natural Cytotoxicity Triggering Receptor 3IBA 06/2015 - 04/2011
2	HLA-DR4 Antigen (HLA DR4 Antigen)IBA 11/2013 - 03/2011
2	Myelin Basic ProteinIBA 03/2011 - 09/2005
1	Interferon Type IIBA 12/2023
1	Nucleic AcidsIBA 12/2023
1	AutoantigensIBA 01/2023
1	Cancer VaccinesIBA 01/2023
1	SARS-CoV-2 spike proteinIBA 10/2022
1	voglibose (Basen)IBA 12/2021
1	valiolamineIBA 12/2021
1	NectinsIBA 01/2019
1	LipidsIBA 01/2017
1	Complement System Proteins (Complement)IBA 12/2016
1	Broadly Neutralizing AntibodiesIBA 12/2016
1	Interleukin-12 (IL 12)IBA 07/2015
1	Interleukin-10 (Interleukin 10)IBA 07/2015
1	Interleukin-8 (Interleukin 8)IBA 07/2015
1	Membrane Proteins (Integral Membrane Proteins)IBA 06/2015
1	Thomsen-Friedenreich antigenIBA 08/2013
1	LectinsIBA 08/2013
1	Polysaccharides (Glycans)IBA 08/2013
1	Carbohydrate Tumor-Associated Antigens (Antigens, Tumor-Associated Carbohydrate)IBA 01/2013
1	ExotoxinsIBA 01/2013
1	peptidoglycan recognition proteinIBA 01/2013
1	Pathogen-Associated Molecular Pattern MoleculesIBA 10/2012
1	Methicillin (Metin)FDA Link 01/2011
1	Indicators and Reagents (Reagents)IBA 01/2011
1	PhosphopeptidesIBA 06/2010
1	Cadherins (E-Cadherin)IBA 07/2009
1	Bacterial ToxinsIBA 08/2007
1	Interleukin-2 (IL2)IBA 07/2007
1	Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA 07/2007
1	staphylococcal enterotoxin IIBA 09/2006
1	ZincIBA 09/2006
1	Hemagglutinins (Hemagglutinin)IBA 09/2006
1	HLA Antigens (Human Leukocyte Antigens)IBA 09/2005
1	Natural Killer Cell ReceptorsIBA 06/2003
1	Natural Cytotoxicity Triggering Receptor 2IBA 06/2003
1	Neoplasm Antigens (Tumor Antigens)IBA 05/2002
1	EnzymesIBA 05/2002

Therapy/Procedure

6	Immunotherapy 03/2024 - 05/2002
3	Cell- and Tissue-Based Therapy (Cell Therapy) 01/2023 - 01/2020
3	Therapeutics 01/2023 - 05/2002